Sanofi-aventis and Oxford Biomedica Report Encouraging Trovax® Phase II Trial Results in Metastatic Renal Cancer
Sanofi-aventis and Oxford Biomedica Report Encouraging Trovax® Phase II Trial Resultsin Metastatic Renal Cancer- Presentations at the American Society of Clinical OncologyAnnual Meeting -Paris, France and Oxford, UK - 2 June 2008: Sanofi-aventis (Euronext: SAN and NYSE: SNY) and Oxford BioMedica (LSE: OXB) announced today encouraging updated results from Phase II trials of TroVax in metastatic (advanced) renal cancer.TroVax is Oxford BioMedica’s lead therapeutic cancer vaccine, which is being developed in metastatic renal cancer and other solid cancers in collaboration with sanofi-